May. 12 at 7:23 PM
$ZVRA Just fyi:
"On May 12, 2026, Collegium Pharmaceutical completed its previously announced
$650 million cash acquisition of the AZSTARYS ADHD business from Corium Therapeutics, adding a central nervous system stimulant with patent protection expected through 2037 to its growing ADHD portfolio."
"The deal, funded with a mix of cash and term loan financing plus potential milestone payments, prompted the company to raise its 2026 guidance, projecting net product revenues of
$865 million to
$895 million, adjusted EBITDA of
$475 million to
$500 million, and
$60 million to
$70 million in AZSTARYS revenue as it targets over
$50 million in annual synergies."
"The company also announced leadership changes, with Chief Commercial Officer Scott Dreyer set to depart at the end of August 2026 and Chief Medical Officer Thomas Smith, M.D., to leave following a transition period, signaling an operational reshaping as Collegium integrates AZSTARYS and pursues an expanded role in the ADHD market."
